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Summary: In this issue of Cancer Discovery, Guagnano and colleagues utilise a large 
and diverse annotated collection of cancer cell lines, the “Cancer Cell Line Encyclopedia”, 
to correlate whole genome expression and genomic alteration datasets with cell line 
sensitivity data to the novel pan-FGFR inhibitor NVP-BGJ398. Their findings not only 
underscore the preclinical utility of such cell line panels in identifying predictive 
biomarkers, but also the emergence of the FGFRs as valid therapeutic targets, across an 
increasingly broad range of malignancies. 
 
Given the high cost of oncology drug development, there exists a financial, as well 
as ethical, imperative to utilize our understanding of cancer biology to incorporate 
predictive biomarkers into patient stratification at the earliest stages of clinical drug 
development. Using such a strategy in Phase I/II clinical trials is expected to alleviate to 
some extent the high cost and prolonged time associated with oncology drug approval, 
and ultimately lead to the co-approval of accompanying diagnostic tests for patient pre-
selection. Examples of drugs that have successfully utilized predictive biomarker assays 
within the original Phase I trial, as well as subsequent Phase II/III trials, include the ALK 
inhibitor crizotinib in patients with EML4-ALK fusions and the BRAF inhibitor vemurafinib 
in BRAF-mutant melanoma patients (1).  
 
Despite the established limitations of monolayer cultures as models for anticancer 
drug response, large-scale cancer cell line collections, well-annotated at the DNA, RNA 
and chromosome levels, represent powerful resources in identifying biomarkers of drug 
sensitivity. Building upon the success of the original NCI60 cancer cell line panel, several 
groups have established larger and more diverse cancer cell line libraries to better capture 
the lineage and genomic diversity of cancer. These efforts largely reflect the well-accepted 
notion that by and large cancer is a disease of genetics - as well as the clinically unmet 
need to identify reliable predictive biomarkers for patient stratification. To underscore their 
utility in this endeavour, large well-annotated cell line platforms have already revealed 
both known and novel predictors of preclinical efficacy to various cancer therapeutics (2-
4). An apt illustration of this is the study by Garnett and colleagues, whose analyses of 
639 human tumour cell lines across 130 drugs not only confirmed several expected 
genomic correlates of drug response, such as lapatinib sensitivity in cell lines with ERBB2 
amplification, but also uncovered novel associations, including PARP inhibitor sensitivity in 
Ewing’s sarcoma cells with a EWS-FLI1 gene translocation (3). 
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This issue of Cancer Discovery features an study by Guagnano and colleagues at 
the Novartis Institutes for Biomedical Research that aimed to identify predictive 
biomarkers for the novel and selective FGFR inhibitor, NVP-BGJ398 utilizing the “Cancer 
Cell Line Encyclopedia” (CCLE), which they developed in conjunction with the Broad 
Institute (5). To this end, they performed two independent high-throughput cell viability 
screens using a panel of 541 cell lines from the CCLE followed by confirmatory manual 
cell proliferation assays in a subset of lines. In this manner they identified a subgroup (n = 
32) of cancer lines sensitive to NVP-BGJ398. Of note, these 32 cell lines comprised 
approximately 6% of all cell lines tested and 13 different cancer types, including the novel 
finding of NVP-BGJ398 sensitivity in single cell lines derived from osteosarcoma and 
colon cancer. By utilizing gene expression and genomic alteration datasets from the 541 
cell lines, the authors then sought to identify predictive biomarkers of drug sensitivity to 
NVP-BGJ398 using a predictive categorical model approach with more than 50,000 input 
features. These included individual genomic features, expression signatures and a 
composite “FGFR genetic alteration” feature that combined 8 distinct types of FGFR 
genetic alterations including copy number gains, activating mutations and chromosomal 
translocations. From the more than 500 cell lines studied, approximately 7% (37/541) 
harboured genetic aberrations in one of the four FGFRs, consistent with the reported 
frequency of FGFR activation in cell lines derived from various tumour types (6, 7).  
 
Perhaps not surprisingly, integrative analysis revealed the composite “FGFR 
genetic alteration” as the most robust predictive input of NVP-BGJ398 sensitivity, 
confirming the expected relationship between NVP-BGJ398 and previously characterized 
models of FGFR dependence (7, 8). Data with other clinically relevant FGFR inhibitors 
has been reported previously for most of the FGFR inhibitor sensitive cell lines with FGFR 
genetic alterations (8-11). However, the current study adds to the field by showing that 
very few cell lines without a known dependency on an FGFR, or a gene expression 
signature characteristic of FGF signalling, do indeed show sensitivity to NVP-BGJ398. The 
authors also show that the presence of an FGFR alteration by no means guarantees drug 
sensitivity as only half of all FGFR altered lines (17/37- 46%) were found to be sensitive. 
With respect to new indications, this study was also the first to report an FGFR1 
amplification in 1/7 osteosarcoma cell lines and functional validation of FGFR1 
dependence using shRNA knockdown of FGFR1. Screening of primary tumors showed 
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FGFR1 amplification in 1/17 primary osteosarcoma samples. Although no functional data 
is presented, the authors expand on the known importance of FGFR2 amplification in 
gastric cancer by reporting amplification of FGFR2 in 1/22 oesophageal tumors, 
suggesting yet another tumour type where FGFR inhibition may have therapeutic value.  
 
Of clinical significance, approximately half of the cancer cell lines with FGFR 
genomic alterations did not respond to NVP-BGJ398. Perhaps surprisingly, the majority of 
non-responsive cell lines carried FGFR1 amplifications and were derived from lineages 
previously shown to be dependent on FGFR1 e.g. breast and lung cancer cell lines. Of the 
13 cell lines identified with FGFR1 amplification, only 5/13 (38%) were found to be 
sensitive to NVP-BGJ398 in contrast to 3/3 cell lines with FGFR2 amplifications. The 
authors propose that additional genetic alterations may bypass FGFR dependency (e.g. 
one lung cancer cell lines with an FGFR1 amplification also carried a KRAS mutation) or 
that other genes found in the gistic peak may be the bona fide “oncogenic driver”. Given 
there are currently multiple trials of anti-FGFR agents where FGFR1 amplification is one 
of several FGFR biomarkers being used to stratify patients upfront e.g. NVP BGJ398 
(NCT01004224) or in a Phase 1b expansion cohorts e.g. E3810 (NCT01283945) and 
AZD4547 (NCT00979134), the field eagerly awaits mature patient response data from 
these early trials. It may be that the work presented in this manuscript foretells the 
necessity for additional biomarkers of sensitivity or resistance for better stratification of 
patients with FGFR1 amplified tumors. The difficulty in distinguishing which gene in an 
amplicon is the biological “driver” is especially true for FGF19, located within the same 
amplicon as CCND1 and amplified in 49/541 cell lines. To circumvent this problem, the 
authors looked for lineage specific coexpression of other genes and identified the 
combination of FGF19 amplification and β-Klotho expression as predictive biomarkers of 
drug sensitivity in liver cancer cell lines. In contrast to the development of BRAF inhibitors 
where patient stratification and the development of a companion diagnostic was relatively 
straightforward, the success of FGFR inhibitors will likely involve the development of 
predictive biomarkers that are largely lineage-specific. With distinct mechanisms of FGFR 
activation presenting in particular tumor types, it is quite possible that the various FGFR 
inhibitors developed by industry will have different companion diagnostics depending on 
the major tumor type for which they were initially approved, such as FGFR1 amplification 
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in breast cancer, FGFR2 amplification in gastric cancer or FGFR3 mutation in bladder 
cancer. 
 
To better refine biomarkers of sensitivity and resistance, one approach could be to 
characterize additional cell lines or patient derived xenograft models carrying the range of 
aberrations in FGF/FGFR family members associated with sensitivity to FGFR inhibition. 
However in many cases this is cost and time prohibitive.  Alternatively, as evidenced from 
a large number of molecularly targeted agents, much can be learned from reverse 
translation studies with clinical tumor material obtained from patients either pre and/or 
post drug treatment (1). To truly increase our knowledge in this area, benefit the most 
patients in the shortest period of time, and gain insights into both intrinsic and acquired 
mechanisms of resistance, all trials of anti-FGFR agents should focus on collecting tumor 
biopsies, ideally before treatment, post treatment and if - or when - resistance emerges.  
 
As FGFR inhibitors gain increasing clinical recognition, one major question that 
remains unanswered is whether multi-kinase inhibitors or specific FGFR inhibitors will 
provide the most durable clinical responses in those patients preselected with FGFR 
activation. How does the potential for more durable clinical responses - as a result of 
inhibiting alternate kinase pathways associated with intrinsic and acquired resistance - 
balance against the increased toxicity associated with a broader inhibition profile. This will 
of course require employing appropriate pharmacodynamic markers (e.g. antibodies to 
detect pan-phospho FGFR) to show that a multi-kinase inhibitor can successfully hit the 
FGFR target or modulate the downstream pathway to the same extent. Finally, the 
evaluation of specific FGFR inhibitors with narrow toxicity profiles may prove especially 
important in those FGFR-dependent malignancies associated with other comorbidities, 
such as endometrial cancer patients with obesity and/or type 2 diabetes. 
 
This cancer cell line screen also draws attention to one of the known bottlenecks 
originally associated with large scale sequencing studies and soon to be increasingly 
associated with clinical trial enrollment i.e. how to interpret novel missense mutations. 
Specifically, if we see a novel mutation in a “druggable” kinase how do we know if it 
results in “oncogene dependence” and is therefore “actionable”? If it occurs in a disease 
setting characterized by FGFR mutations (e.g. bladder or endometrial cancer) we would 
certainly be more hopeful. Nonetheless, inclusion of these patients would likely add 
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unnecessary complexity to interpreting patient response data e.g. in the absence of a 
clinical response did they have an irrelevant passenger mutation or intrinsic resistance to 
FGFR inhibition? Of the four NVP BGJ398-insensitive cell lines, three carried novel and 
uncharacterized mutations in either FGFR1 or FGFR2. Indeed, two of these cell lines were 
derived from tumor types associated with a high “passenger” mutation rate owing to 
environmental mutagen exposure (e.g. lung cancer and melanoma) and thus exemplifying 
the inherent difficulty in distinguishing passenger from oncogenic driver mutations. As 
such, until functional data is published on novel FGFR missense mutations, we would 
propose that early proof-of-principle trials of anti-FGFR agents enroll only those patients 
with known activating mutations.  
 
In summary, Gaugnano and colleagues provide strong evidence that FGFR genetic 
alterations drive carcinogenesis in a broad range of malignancies and in doing so 
demonstrate not only the preclinical utility of large genetically annotated cell line panels to 
identify predictive biomarkers but also the specificity of NVP-BGJ398. Ongoing work to be 
performed alongside the clinical development of anti-FGFR agents include among others: 
further refining the level of gene amplification associated with a clinical response for each 
receptor; validation of either in situ hybridization or immunohistochemistry in formalin-fixed 
paraffin embedded pathology specimens as a companion diagnostic for receptor 
amplification, and finally correlative studies between different mutations in different FGFRs 
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